Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02555644 · ClinicalTrials.gov registry record · Phase 1
A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
NCT02555644 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 70 participants.
The verdict
NCT02555644, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
Study Summary
The main purpose of this study is to investigate the safety of prexasertib in combination with other anti-cancer drugs (cisplatin or cetuximab) and radiation therapy in participants with locally advanced head and neck cancer. The study has two parts (A and B). Participants will only enroll in one part.
Interventions
- DRUG Cisplatin
- DRUG Cetuximab
- RADIATION Intensity Modulated Radiation Therapy
- DRUG Prexasertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2016-02-24 |
| Est. Completion | 2019-01-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02555644
The ClinicalTrials.gov registry entry for NCT02555644 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cisplatin is the first listed.
NCT02555644 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02555644 about?
NCT02555644 is a clinical study titled "A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer". The main purpose of this study is to investigate the safety of prexasertib in combination with other anti-cancer drugs (cisplatin or cetuximab) and radiation therapy in participants with locally advanced head and neck cancer. The study has two parts (A and B). Participants will only enroll in one pa...
What is the current status of trial NCT02555644?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2016-02-24. Estimated completion is 2019-01-14.
What interventions are being tested in trial NCT02555644?
The interventions under investigation include: Cisplatin (DRUG), Cetuximab (DRUG), Intensity Modulated Radiation Therapy (RADIATION), Prexasertib (DRUG).
Who is sponsoring clinical trial NCT02555644?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.